TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$288 Million

Immunomedics, Inc.

Follow-on Offering

Bookrunner, December 2019

Immunomedics, Inc.
Immunomedics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxicities that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics’ most advanced ADCs are sacituzumab govitecan (IMMU- 132) and labetuzumab govitecan (IMMU-130), which are being studied for a number of solid tumors and metastatic colorectal cancer, respectively.